The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification

This study reassesses the diagnostic value of PSMA PET/CT in unfavorable intermediate-risk prostate cancer (PCa) and validates the Prostate Cancer Network the Netherlands (PCNN) subclassification. Men subjected to PSMA PET/CT were analyzed, evaluating the incidence of metastatic disease and its corr...

Full description

Saved in:
Bibliographic Details
Published in:Prostate cancer and prostatic diseases 2024-09
Main Authors: Hagens, Marinus J, Luining, Wietske I, Boevé, Liselotte M S, Knol, Remco J J, Roeleveld, Ton A, Srbljin, Sandra, Weltings, Saskia, Koppes, Jose C C, Oprea-Lager, Daniela E, Vis, André N, van Leeuwen, Pim J, van der Poel, Henk G
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study reassesses the diagnostic value of PSMA PET/CT in unfavorable intermediate-risk prostate cancer (PCa) and validates the Prostate Cancer Network the Netherlands (PCNN) subclassification. Men subjected to PSMA PET/CT were analyzed, evaluating the incidence of metastatic disease and its correlation with PCNN subgroups. Metastatic disease was identified in 12.4% of patients. Higher PCNN subgroups correlated with increased metastatic potential; odds were significantly lower in low metastatic potential cases (OR: 0.19, 95% CI 0.06-0.62; p = 0.01). Our findings reaffirm PSMA PET/CT's diagnostic value in unfavorable intermediate-risk PCa and validate the PCNN subclassification, reducing scan burden by 48.1%.
ISSN:1365-7852
1476-5608
1476-5608
DOI:10.1038/s41391-024-00899-9